Wed, Jan 28, 2015, 5:22 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Aeterna Zentaris Inc. Message Board

PatientMD 14 posts  |  Last Activity: Jan 21, 2015 3:40 PM Member since: Jan 29, 1999
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • patientmd patientmd Jan 21, 2015 3:40 PM Flag

    Having been an investor for over 10 years, the only positive event was splitting off the vitamin company which resulted in less of a total loss in investment. Unfortunately, your analysis and comments are right on!!!!!
    With more dilutions and reverse splits, even a successful phase 3 will only result in a modest recovery of losses and that assumes that management can be successful at anything.

    Sentiment: Hold

  • Reply to

    Undervalued. Accumulate and hold.

    by bestcityvancouver Dec 8, 2014 10:20 AM
    patientmd patientmd Jan 21, 2015 3:29 PM Flag

    undervalued???? promises, promises.........I have lost a fortune on this stock because of 3 failures to pass phase 3 or the last gain an FDA approval. The first 2 involved drugs with great phase 2 although small size and company "blindsided" by poor phase 3 ( KERX survived and flourished reaching new highs post ffailure).
    The last it seems was destined to fail with comments from the FDA and I do not understand why company even went forward following those. Because of the above failures , stock dropped and dropped and then reversed split and dropped and drop some more.
    Does anyone really believe that this company can complete a FDA approved phase 3 with success and then get approval??? If their track record is any evidence against this happening, this stock is overvalued at present. At ..57, I will continue to hold and hope management will finally reward shareholders. In meantime, all stock options should be suspended or at least tied to the stock price; otherwise, the only beneficiaries of all these failures continue to the management team.

    Sentiment: Hold

  • do not understand why shorts are so interested in this $3 stock? isn't there more to be gained by shorting a higher price stock and driving it downward? Other than reporting higher revenues and earnings is there anything the company can do to blunt the effect of the shorts and naysayers? It seems that the good news at the end of last quarter had a short term positive effect and then the stock headed south. In the face of a healthy stock market and news better than expected, why has this stock failed to maintain an upward trend?
    Would it help if management offered to connect their stock options and bonuses with performance of the stock ( and therefore have more skin in the game like us investors) and also managed their selling and disposal of these gifted shares in a more appropriate time frame so as not to dampen even small upward blips in stock?

    Sentiment: Strong Buy

  • Reply to

    cachet financial solutions-leading provider????

    by patientmd Dec 9, 2014 5:44 PM
    patientmd patientmd Dec 10, 2014 3:39 PM Flag

    sarcasm??? obviously, pleased with NCR announcement!

    Sentiment: Strong Buy

  • Just curious what kind of leading provider of financial services is trading at less than $1.50
    and has so little cash in the account?? Aren't there more substancial providers interested in partnering with Mitek? This partnership agreement certainly does not excite the Street so far or myself. Am I wrong to feel this way about it?

    Sentiment: Strong Buy

  • As Mitek drifts downward slightly and volume low after positive earnings, do we have to wait 3 months for hopefully another good report to propel the stock upward or what other factors might cause it to move upwards

    Sentiment: Strong Buy

  • Better than expected good news and the response of stock disappointing! Explanation?
    What is it going to take to have this stock make a sig move upwards? How does stock counter the grip the shorts seem to have? Bad news pummels the stock and yet good news barely moves it.

    Sentiment: Buy

  • During CC, current management shifted responsibility of purchasing rights to Marilen on previous management team who apparently reviewed and liked phase 2 studies done by another company.
    Current management unclear and shifted to one another but it appears that they accepted phase 2 studies done elsewhere and did not do due exhaustive review of their own before starting phase 3. This does not seem like an appropriate course of action.
    To make things worse, after phase 3 data in ( over 2 years ago) why didn't the FDA review the results
    and point out the tragic flaws of the phase 2 and 3 studies before encouraging or permitting AEZS to go forward with the time consuming, costly, diluting process to obtain NDA? The last 2 years were a total waste of resources and time and never should have occurred if the FDA would have acted responsibility and alerted the company to the flaws. Approval never had a chance.
    So who to blame for this fiasco???? Current management for pushing forward without really determining the validity of previous studies and accepting previous management's assessment.!! The FDA for not providing the guidance necessary to halt process of seeking approval.
    The losers, we shareholders again!!!!!!!!
    How much of us have confidence that AEZS can plan and carryout a successful phase 3 on endometrial cancer drug????

    Sentiment: Sell

  • Since it seems that the sales force hired for Macrilen was linked to Ascend's sales reps, what does the future hold?? Why would Ascend tie its future to a company like AEZS at this time? Wouldn't count on it!!!

    Sentiment: Sell

  • I hope some analyst or private investor(although I bet won't be given the chance by company to ask)
    has the guts to ask " in view of the harsh CRL by FDA yesterday it seems that the company spent 2 years and considerable resources trying to get approval of drug that never had a chance based on company's phase 3,
    why???? Secondly, with your track record which includes Marcrilen and the last 2 surprises of prostate drug and colorectal drug ( maybe they weren't such surprises) how can we trust the company to intelligently
    plan drug phase trials, accurately assess the results, and honestly report to the investing community???.
    If we all have lost confidence, the pipeline which continually is shrinking is imaginary and worthless.
    Management needs to take bold initiative like suspending bonuses, options and even reducing salaries until they actually perform.

    Sentiment: Sell

  • Anyone on this board believe management can manage and/or deliver on any drug??? Either through misinterpretation and bad advice or more worrisome misrepresentation of the facts, despite positive PR they have failed miserably 3x. Therefore, I believe that there is no viable pipeline!!!!!!! However, they will pursue
    development of it as long as there are funds for their salaries and bonuses. Save the 43M and divide it among the shareholders.
    I have lost a lot of $$ on this long trek to nowhere ( thank goodness they spun off the vitamin company and it paid well). They never intended to develop Macrilen but were forced to when the colorectal drug failed.
    How could they have moved forward and spent time and money past 3 years in the face of such a condemnation from the FDA? So many flaws could not or should not have been a surprise.

    There is no way the company can make lemonade from this lemon announcement. The bitter taste will last a long time. Still not sure why 8M shares traded day before announcement. Were these who sold lucky?
    Clairvoyant? Or privy to information from FDA or company that rest of us did not have?
    Investigation needs to be done and all held accountable.

    Sentiment: Strong Sell

  • 3x and your out; this is third time that management failed miserably to deliver results promised; this is worst with the letter from the FDA indicating that time and money wasted for past 3 years all the time either misinterpreting the results of studies and communication with FDA or misrepresenting them; No matter,
    do not believe anything company states anymore and truly believe that because of this THERE IS NO VIABLE PIPELINE and that there will be lawsuit which they will not be able to defend ( not able to defend their bonuses and salaries either). 8M shares traded 2 days ago. We shareholders in small companies have no chance with either the leak at the company level or the FDA and this should also be investigated and if the latter FDA should be accountable for losses ( fat chance) if someone there is leaking to the investing public prior to bad news.

  • Reply to

    One last thought on delay...and halt...

    by upsidefz Nov 5, 2014 7:27 PM
    patientmd patientmd Nov 5, 2014 8:11 PM Flag

    unfortunately, wrong!! Bumped up sales force before as well as hiring more management only to fall flat on face when the prostate drug and then the colon cancer drug failed phase 3

  • patientmd patientmd Nov 4, 2014 6:05 PM Flag

    unfortunately, I have been a shareholder for over 10 years and have seen the "red flags" before with the
    drop in share price prior to an announcement, which in every case has been "bad news" with failures of phase 3 results when positive news was expected confirming fact there are no secrets except those from the smaller investors. I hope gog..... is wrong about this one and the news is positive. Will wait nervously for tomorrow's announcement and hope that management have complied with all FDA's requests and no more delays ( over 2 years now)

    Sentiment: Hold

AEZS
0.53+0.010(+1.92%)Jan 28 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.